Genentech, Inc.

Merck + Co., Inc.

Axys Pharmaceuticals, Inc.

Newlink Genetics Corporation

F. Hoffmann-la Roche Ag

Rohan V Mendonca

Lei Zhang

Lewis J Gazzard

Bryan K Chan

Jun Liang

Timothy Heffron

Michael Siu

Joy Drobnick

John Tellis

Andrew Madin

Sushant Malhotra

Emanuela Gancia

Michael Lainchbury

Craig Stivala

Kin Chiu Fong

Yonghan Hu

Matthew W Cartwright

David Favor

Andrew Good

BinQing Wei

Graham Elgin Jones

Mark Edward Zak

Weiru Wang

Naomi S Rajapaksa

Aihe Zhou

Richard Pastor

Binqing Wei

Terry Kellar

Wei Li

Joseph P Lyssikatos

Nicholas Charles Ray

Zhonghua Pei

Po-Wai Yuen

Simon Charles Goodacre

Emily J Hanan

Paul Gibbons

Yun-Xing Cheng

Guosheng Wu

Aijun Lu

Malcolm Huestis

Blake Daniels

Baihua Hu

Wendy Liu

Shankar Venkatraman

Brendan Parr

Bing-Yan Zhu

Janusz Jozef Kulagowski

Peter Scott Dragovich

Steven R Magnuson

Po-wai Yuen

Ann Marie Buysse

Hazel Joan Dyke

Christopher Hurley

Sharada Shenvi Labadie

Firoz Jaipuri

James T Palmer

Eduardo Setti

Srinivasan Babu

Jesse Waldo

Thomas E Rawson

Stuart Ward

Sanjeev Kumar

Zong-Qiang Tian

Joel S Robichaud

Hima Potturi

Xingyu Lin

Bohdan Waszkowycz

Benjamin Douglas Sellers

Renata Oballa

Elise Isabel

Dan-Xiong Wang

Edna F Choo

Roheeth Pavana

Xiaokai Li

Venkata Velvadapu

Rebecca Pulk

Michael Koehler

Tony Johnson

Stefan Gradl

Phillippe Bergeron

Zuhui Zhang

Po-Wei Yuen

Naomi Rajapaksa

John C Tellis

3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.

Isoquinoline compounds for the treatment of cancer

Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinoline compounds and uses thereof

Naphthyridine compounds and uses thereof

3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.

8-aminoisoquinoline compounds and uses thereof

Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer. 

TDO2 and IDO1 inhibitors

Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinolines as inhibitors of HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Naphthyridines as inhibitors of HPK1

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

TDO2 Inhibitors

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R, Rand Rare defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed. 

Pyrazolopyrimidine JAK inhibitor compounds and methods

The invention provides novel compounds of formula I having the general formula: wherein R, R, R, X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

Tricyclic heterocyclic compounds, compositions and methods of use thereof

Compounds and compositions as protease inhibitors

Growing community of inventors

South San Francisco, CA, United States of America

Rohan V Mendonca